Nasdaq LogoVeeva Logo

Market & Financial Intelligence Platforms · vs · Cloud Cybersecurity & Infrastructure Resilience

Nasdaq vs Veeva

Structured technology and market comparison · 2026

Direct Feature Comparison

Nasdaq · vs · Veeva
Direct Feature Comparison: Nasdaq vs Veeva
Attribute
Nasdaq LogoNasdaq
Veeva LogoVeeva
Market Cluster / SectorMarket & Financial Intelligence PlatformsCloud Cybersecurity & Infrastructure Resilience
Business Model / RoleData Provider / BrokerData Provider / Broker
Platform FocusCapital markets infrastructure, financial data and enterprise fintech provider.Life sciences cloud software and data platform provider.
Company Size>5,000 employees>5,000 employees
HeadquartersUnited StatesUnited States
Year Founded19712007
Dossier & Alternatives

Analyze all overlapping signals and tech stacks for Nasdaq and Veeva

Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.

Compare in PlatformInstant access · 1-click via Google/LinkedIn

Comparison Analysis

What is the main difference between Nasdaq and Veeva?

When comparing Nasdaq and Veeva, both platforms operate within the Cloud Data Warehouse / Data Lake, Data Provider / Broker, and Measurement & Analytics Platform ecosystem. Nasdaq is positioned as Capital markets infrastructure, financial data and enterprise fintech provider, whereas Veeva focuses on Life sciences cloud software and data platform provider. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.

What are the top alternatives to Nasdaq and Veeva?

When evaluating Nasdaq and Veeva, enterprise buyers also consider other platforms in Cloud Data Warehouse / Data Lake, Data Provider / Broker, and Measurement & Analytics Platform. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.

How do the corporate scale, structure, and headquarters of Nasdaq and Veeva compare?

Nasdaq is headquartered in United States (founded in 1971) with >5,000 employees. Veeva is based in United States (founded in 2007) with >5,000 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.

Market Signals

Recent Market Signals & Activity: Nasdaq vs Veeva

Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.

Nasdaq Logo

Nasdaq

Recent Signals

  • ·SEC APIfinancials

    Anthropic Files S-1/A Targeting Up to $64.4B IPO and $26.0B Strategic Placement

    Anthropic, PBC filed Amendment No. 2 to Form S-1 with the SEC on November 10, 2026, registering an IPO of 825,000,000 Class A common shares (801,351,354 primary, 23,648,646 secondary) at $70.00–$78.00 per share, targeting up to ~$64.4B in gross proceeds. The offering includes a concurrent $26.0B private placement of Class N non-voting stock to strategic partners such as Google, NVIDIA, AMD, Broadcom, Micron, Microsoft, and TSMC. For the nine months ended September 30, 2026, revenue surged 1,206% YoY to $33.24B, with an operating loss narrowing to $1.26B, but net loss widened to $104.04B due to a $94.32B non-cash fair value adjustment on convertible notes. Compute purchase and lease commitments total ~$900.9B. The IPO faces protest from 'Stop Funding Billionaires' at Nasdaq's Times Square office, warning of pension fund risks. Analysts note rapid index inclusion is possible but S&P 500 entry is unlikely before 2027.

    • Anthropic registers 825.0M Class A shares at $70.00–$78.00 per share, with a concurrent $26.0B Class N private placement to strategic partners like Google and NVIDIA ($10.0B each).
    • Nine-month revenue reached $33.24B (up 1,206% YoY), operating loss narrowed to $1.26B, but net loss hit $104.04B due to $94.32B non-cash fair value adjustments on convertible notes.
    • Total compute purchase and lease commitments stand at ~$900.9B, with $70.7B due within 12 months.
  • ·SEC APILeadership & People

    Nasdaq Appoints Laura DeLorenzo as Principal Accounting Officer Effective January 2027

    On November 18, 2026, Nasdaq, Inc. announced an executive accounting leadership transition effective January 1, 2027. Michelle L. Daly has resigned from her role as Senior Vice President, Controller and Principal Accounting Officer to transition internally into the role of Business Unit Chief Financial Officer and Head of Strategy & Revenue Operations for the Capital Access Platforms Division. Laura DeLorenzo, currently serving as Vice President, Head of Global Reporting and Accounting Policy, has been appointed as Senior Vice President, Chief Controller and Principal Accounting Officer to succeed Daly. DeLorenzo brings extensive internal reporting expertise alongside nine years of previous audit practice at Ernst & Young LLP. Compensatory arrangements for DeLorenzo's new position will be filed via an amendment once finalized.

    • Michelle L. Daly steps down as SVP, Controller and Principal Accounting Officer effective January 1, 2027, transitioning to BU CFO and Head of Strategy & Revenue Operations for Capital Access Platforms.
    • Laura DeLorenzo is appointed Senior Vice President, Chief Controller and Principal Accounting Officer, effective January 1, 2027.
    • DeLorenzo has led Global Reporting and Accounting Policy at Nasdaq since January 2022 and previously spent nine years at Ernst & Young LLP.
  • ·SEC APIM&A & Corporate Finance

    Nasdaq Reports Q3 2026 Net Revenues Up 12.6% to $1.48B

    Nasdaq, Inc. reported its financial results for the third quarter ended September 30, 2026. Revenues less transaction-based expenses rose 12.6% year-over-year to $1,481 million, compared to $1,315 million in Q3 2025. Total gross revenues reached $2,393 million, supported by double-digit expansion across Capital Access Platforms (up 20.2% to $641 million) and Financial Technology (up 15.8% to $529 million). Operating income expanded 24.9% to $732 million, reflecting operational leverage and expense control following the completion of the Adenza restructuring program. GAAP net income attributable to Nasdaq grew 27.8% to $540 million, or $0.96 per diluted share, while non-GAAP diluted earnings per share reached $1.04. Strong performance across index licensing, SaaS-based financial technology solutions, and robust cash equity market share underpinned quarterly execution.

    • Revenues less transaction-based expenses reached $1,481 million in Q3 2026, up 12.6% year-over-year from $1,315 million.
    • GAAP operating income increased 24.9% to $732 million, and net income attributable to Nasdaq increased 27.8% to $540 million ($0.96 per diluted share).
    • Index business achieved record trailing twelve-month net inflows of $141 billion, bringing licensed ETP assets under management to $1.2 trillion.
Veeva Logo

Veeva

Recent Signals

  • ·SEC APIfinancials

    8-K Financial Filing Analysis for Veeva (2026-11-06)

    On November 5, 2026, Veeva Systems Inc. furnished a Form 8-K under Item 2.02 detailing updates provided at its 2026 Investor Day presentation. Chief Financial Officer Brian Van Wagener confirmed that the company expects its third quarter fiscal year 2027 financial results to meet or exceed the preliminary guidance initially issued during its August 26, 2026 earnings conference call. The affirmation reflects operational stability and execution momentum across Veeva's life sciences cloud and data software portfolio as it progresses through the second half of fiscal 2027.

    • During its Investor Day on November 5, 2026, Veeva reaffirmed that Q3 FY2027 financial performance is expected to meet or exceed prior guidance.
    • The baseline guidance referenced was previously issued during the quarterly earnings conference call on August 26, 2026.
    • CFO Brian Van Wagener delivered the financial presentation, referencing guidance materials furnished via Exhibit 99.1.
  • ·PR Newswire: Advertising & MarketingAI in Life Sciences Marketing

    Veeva Summit to Showcase Agentic AI and Data Innovations

    Veeva Systems announced that leaders from AstraZeneca, Bristol Myers Squibb, Grünenthal, Novo, Roche, UCB, and other biopharma companies will present new strategies for commercial and medical excellence at the Veeva Commercial Summit, Europe, scheduled for November 18-19, 2026, in Copenhagen. The summit will showcase how industry-specific AI enables sales, marketing, and medical teams to improve customer engagement, derive insights, and accelerate compliant content delivery. Key topics include agentic customer engagement, agentic CRM, agentic MLR for content approvals, and building a data foundation for AI with HCP access data and trusted data platforms. The event will feature over 100 sessions and 1,200+ industry experts, highlighting innovations with Veeva's Commercial Cloud and Data Cloud.

    • Veeva Commercial Summit Europe is scheduled for November 18-19, 2026, in Copenhagen.
    • The summit will feature over 100 sessions and 1,200+ industry experts.
    • AstraZeneca, Bristol Myers Squibb, Grünenthal, Novo, Roche, and UCB will present case studies.
  • ·PR Newswire: Technology NewsPartnership

    IQVIA Expands Veeva Partnership with Clinical Operations Applications

    IQVIA and Veeva Systems announced an expansion of their partnership, with IQVIA selecting Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications for its clinical development studies. This extends the previously announced EDC partnership. The collaboration aims to increase trial speed and efficiency, strengthen site centricity, and improve decision-making for clinical research customers. All Veeva clinical solutions will also be available through IQVIA for sponsors seeking a full Veeva technology stack. Executives from both companies emphasized the benefits of integrated technologies and customer flexibility in choosing EDC, RTSM, and eCOA solutions. The announcement was made on October 13, 2026, ahead of the Veeva R&D and Quality Summit scheduled for October 20-21 in Boston.

    • IQVIA selected Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications.
    • Partnership expansion extends the previously announced EDC partnership.
    • All Veeva clinical solutions will be available through IQVIA for sponsors.

Start with a company or market. Track what changes.

Create your Polaris7 workspace to explore extended company profiles, organize relevant players into Watchlists, and receive focused briefings when material changes occur.